Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold
Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold